A new drug designed to assist in stem cell transplants will be studied in a Phase 2 clinical trial. TG-0054, created by TaiGen Biotechnology, was effective at moving stem cells from the bone marrow into the blood during the Phase 1 trial.

This drug may help patients collect enough stem cells for stem cell transplantion. Patients suffering from disorders of the blood, bone marrow, or certain cancers receive stem cells, which repopulate the depleted bone marrow with new, healthy blood cells and immune cells.

Stem cells, which are continuously renewed through cell …

A recent Phase 2 study, published in the journal Bone Marrow Transplantation, evaluated Mozobil’s (plerixafor) ability to mobilize stem cells from the bone marrow into the blood without increasing the mobility of tumor cells in multiple myeloma patients.

One common treatment option available to eligible myeloma patients is high dose chemotherapy followed by autologous stem cell transplantation. Before chemotherapy, the patient’s own stem cells are collected by peripheral blood apheresis, which looks and feels similar to a routine blood donation, and then the stem cells are transplanted back after chemotherapy.

For …

The paired use of novel drug agents and autologous stem cell transplantation (ASCT) may not be as effective as formerly believed, according to the June issue of the journal Blood.

Treatment for multiple myeloma commonly integrates high dose therapy of novel drug agents with ASCT. However, an article printed in Blood shows that initial treatment with Revlimid (lenalidomide), one of the novel drug agents, corresponds with inhibition of stem cell mobilization and collection for ASCT.

The introduction of novel drug agents, including thalidomide (Thalomid), Revlimid, and Read the full story »